BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 4, 2026
Home » Topics » Regulatory » Patents

Patents
Patents RSS Feed RSS

Musculoskeletal

Genescience Pharmaceuticals discovers new cannabinoid CB2 receptor agonists

Feb. 16, 2024
Genescience Pharmaceuticals Co. Ltd. has described cannabinoid CB2 receptor agonists reported to be useful for the treatment of arthritis, systemic lupus erythematosus, inflammatory bowel disease, allergic contact dermatitis, colitis, autoimmune diseases and pain.
Read More
Cancer

Insilico Medicine presents new CBL-B inhibitors for cancer

Feb. 16, 2024
Insilico Medicine IP Ltd. has divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Shanghai Sinotau Biotech describes new FAP-1 inhibitors for cancer

Feb. 16, 2024
Shanghai Sinotau Biotech Co. Ltd. has identified tyrosine-protein phosphatase non-receptor type 13 (PTPN13; FAP-1; PTP-1E) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Betta Pharmaceuticals divulges new EGFR mutant inhibitors for cancer

Feb. 16, 2024
Betta Pharmaceuticals Co. Ltd. has synthesized EGFR (HER1; erbB1) mutant inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Shanghai Boyue Biotechnology patents new MET and AXL inhibitors for cancer

Feb. 16, 2024
Shanghai Boyue Biotechnology Co. Ltd. has disclosed hepatocyte growth factor receptor (HGFR; MET) and tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.
Read More
Infection

Shaanxi Synthetic Pharmaceutical discovers new compounds for coronavirus acute respiratory syndrome

Feb. 15, 2024
Shaanxi Synthetic Pharmaceutical Co. Ltd. has described compounds reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Read More
Cardiovascular

Nextgen Bioscience presents new autotaxin inhibitors

Feb. 15, 2024
Nextgen Bioscience Co. Ltd. has divulged ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors reported to be useful for the treatment of cancer, fibrosis, cardiovascular, inflammatory, respiratory, metabolic, eye and renal disorders, among others.<
Read More
Cancer

Betta Pharmaceuticals describes new ER-α degradation inducers for cancer

Feb. 15, 2024
Betta Pharmaceuticals Co. Ltd. has identified estrogen receptor α (ER-α; ESR1) degradation inducers reported to be useful for the treatment of cancer.
Read More
Infection

Ohio State University divulges new bacterial topoisomerase inhibitors for S. aureus infections

Feb. 15, 2024
Ohio State University has synthesized DNA topoisomerase II (bacterial) inhibitors reported to be useful for the treatment of Staphylococcus aureus infections.
Read More
Neurology/Psychiatric

Nanjing Tian Yin Jian Hua Pharma Tech patents new RIPK1 inhibitors

Feb. 15, 2024
Nanjing Tian Yin Jian Hua Pharma Tech Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors acting as necroptosis inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, ulcerative colitis, multiple sclerosis, psoriasis, rheumatoid arthritis and Alzheimer’s disease, among others.
Read More
Previous 1 2 … 267 268 269 270 271 272 273 274 275 … 3787 3788 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 4, 2026.
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 3, 2026
  • Depression concept with human, broken brain and heavy rain

    CROI 2026 highlights depression and cognitive vulnerability in HIV

    BioWorld
    The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
  • Concept art for headache

    Slate Medicines launches with focus on headache disorders

    BioWorld Science
    Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing